The Role of <i>TP53</i> Mutations in <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.

Cancers (Basel) · 2022 · PMC8909869 · PMID 35267450

Europe PMC DOI

hedged sentences

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

a slight trendp = 0.14not close (p > 0.1)

37.8 months in the validation cohort, p = 0.006), highlighting a slight trend in the PFS in a multivariate analysis of erlotinib-treated patients (PFS 11.0 vs. 15.0 months, p = 0.14) [ 111 ].

also in 4,078 other papers

showed a trendno p-value reported

A large cohort study showed a trend for TP53 mutations in predicting a worse OS of EGFR -mutated patients receiving targeted therapy with respect to wt TP53 patients (2.9 years vs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.